CoChat
Sign Up
Cited by 322Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system

Hunter, Randy L., Dragicevic, Natasa, Seifert, Kristen, Choi, Dong Young, Liu, Mei, Kim, Hyoung‐Chun, Cass, Wayne A., Sullivan, Patrick G., Bing, Guoying·2007·Journal of Neurochemistry
DOI 10.1111/j.1471-4159.2006.04327.x
Open this paper in CoChat — free account

Abstract

Evidence suggests that chronic inflammation, mitochondrial dysfunction, and oxidative stress play significant and perhaps synergistic roles in Parkinson’s disease (PD), where the primary pathology is significant loss of the dopaminergic neurons in the substantia nigra. The use of anti‐inflammatory drugs for PD treatment has been proposed, and inhibition of cyclo‐oxygenase‐2 (COX‐2) or activation of peroxisome proliferator‐activated receptor gamma (PPAR‐γ) yields neuroprotection in MPTP‐induced PD. Lipopolysaccharide (LPS) induces inflammation‐driven dopaminergic neurodegeneration. We tested the hypothesis that celecoxib (Celebrex, COX‐2 inhibitor) or pioglitazone (Actos, PPAR‐γ agonist) will reduce the LPS‐induced inflammatory response, spare mitochondrial bioenergetics, and improve nigral dopaminergic neuronal survival. Rats were treated with vehicle, celecoxib, or pioglitazone and were intrastriatally injected with LPS. Inflammation, mitochondrial dysfunction, oxidative stress, decreased dopamine, and nigral dopaminergic neuronal loss were observed post‐LPS. Celecoxib and pioglitazone provided neuroprotective properties by decreasing inflammation and restoring mitochondrial function. Pioglitazone also attenuated oxidative stress and partially restored striatal dopamine as well as demonstrated dopaminergic neuroprotection and reduced nigral microglial activation. In summary, intrastriatal LPS served as a model for inflammation‐induced dopaminergic neurodegeneration, anti‐inflammatory drugs provided protective properties, and pioglitazone or celecoxib may have therapeutic potential for the treatment of neuro‐inflammation and PD.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2006.04327.x

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 2

  1. Niehaus I., 2004, New Trends in Alzheimer and Parkinson Related Disorders, 36
  2. 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U · DOI

Cited by

Sorted by citations

Items 301–322 of 322

Related

See all

Metadata

Authors
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G.
Affiliations
  • University of Kentucky (US)
  • Kangwon National University (KR)
Corresponding author
Bing, Guoying
ORCID
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2006-11-20
Volume
100
Issue
5
Pages
1375-1386
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
DOI
10.1111/j.1471-4159.2006.04327.x
OpenAlex
W1629697287
Cited by
322
References
56
Citations by year
2026: 7 · 2025: 7 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 21 · 2020: 13 · 2019: 20 · 2018: 7 · 2017: 20 · 2016: 23 · 2015: 17 · 2014: 17 · 2013: 17 · 2012: 26
FWCI
11.34
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Journal of Neurochemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (AG017963, R01AG017963)
  • National Institute of Neurological Disorders and Stroke (NS 044157, R01NS048191, NS 046426, NS 048191, R01NS044157, R21NS046426)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
Parkinson's disease, neuroinflammation, dopaminergic neuron loss, substantia nigra, mitochondrial dysfunction, oxidative stress, lipopolysaccharide, celecoxib, pioglitazone, COX-2 inhibition, PPARγ agonism, neuroprotection, microglial activation, striatal dopamine, MPTP model
MeSH terms
Celecoxib, Pioglitazone, Animals, Corpus Striatum, Dopamine, Inflammation, Lipopolysaccharides, Male, Mitochondria, Nerve Degeneration, Neurons, Pyrazoles, Receptor, Insulin, Substantia Nigra, Sulfonamides, Cell Death, Rats, Sprague-Dawley, Microglia, Thiazolidinediones, PPAR gamma, Rats, Cyclooxygenase 2 Inhibitors, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review